PDF(Pubmed)
Abstract：
Pradofloxacin is the newest of the veterinary fluoroquinolones to be approved for use in animals-initially companion animals and most recently food animals. It has a broad spectrum of in vitro activity, working actively against Gram-positive/negative, atypical and some anaerobic microorganisms. It simultaneously targets DNA gyrase (topoisomerase type II) and topoisomerase type IV, suggesting a lower propensity to select for antimicrobial resistance. The purpose of this study was to determine the rate and extent of bacterial killing by pradofloxacin against bovine strains of Mannheimia haemolytica and Pasteurella multocida, in comparison with several other agents (ceftiofur, enrofloxacin, florfenicol, marbofloxacin, tildipirosin, tilmicosin and tulathromycin) using four clinically relevant drug concentrations: minimum inhibitory and mutant prevention drug concentration, maximum serum and maximum tissue drug concentrations. At the maximum serum and tissue drug concentrations, pradofloxacin killed 99.99% of M. haemolytica cells following 5 min of drug exposure (versus growth to 76% kill rate for the other agents) and 94.1-98.6% of P. multocida following 60-120 min of drug exposure (versus growth to 98.6% kill rate for the other agents). Statistically significant differences in kill rates were seen between the various drugs tested depending on drug concentration and time of sampling after drug exposure.
摘要：
普拉氧氟沙星是最新的兽用氟喹诺酮类药物，被批准用于动物-最初的伴侣动物和最近的食用动物。它具有广谱的体外活性，积极对抗革兰氏阳性/阴性，非典型和一些厌氧微生物。它同时靶向DNA促旋酶（II型拓扑异构酶）和IV型拓扑异构酶，表明选择抗菌素耐药性的倾向较低。这项研究的目的是确定普拉氧氟沙星对溶血曼海姆氏菌和多杀巴斯德氏菌牛菌株的细菌杀灭率和程度，与其他几种药物(头孢噻呋酯，恩诺沙星,氟苯尼考,马波沙星,吡啶香,替米考星和泰拉霉素）使用四种临床相关药物浓度：最低抑制和突变预防药物浓度，最大血清和最大组织药物浓度。在最大血清和组织药物浓度下，在药物暴露5分钟后，普拉氧氟沙星杀死了99.99％的溶血支原体细胞（相对于其他药物的生长至76％的杀死率），在药物暴露60-120分钟后杀死了94.1-98.6％的多杀性疟原虫（相对于其他药物的生长至98.6％的杀死率）。根据药物浓度和药物暴露后的采样时间，在各种测试药物之间观察到杀死率的统计学显着差异。
